Loading...
XKRX
009420
Market cap1.76bUSD
Dec 05, Last price  
51,100.00KRW
1D
-8.75%
1Q
59.94%
Jan 2017
288.59%
Name

Hanall Biopharma Co Ltd

Chart & Performance

D1W1MN
XKRX:009420 chart
P/E
P/S
18.67
EPS
Div Yield, %
Shrs. gr., 5y
-0.18%
Rev. gr., 5y
5.08%
Revenues
138.94b
+2.99%
82,485,563,00091,890,326,00098,682,408,000106,903,737,00087,701,600,68076,027,305,22074,228,313,77080,879,668,14080,022,559,94082,881,524,07084,230,756,08091,839,350,940108,452,042,40088,602,270,090101,594,443,690109,995,418,980134,909,837,620138,943,699,000
Net income
-1.80b
L
-1,029,708,0001,170,025,000581,952,000213,659,000-14,525,740,000-2,922,595,000-21,498,897,000-12,658,084,910-7,077,356,9502,026,026,4205,813,253,6603,300,102,19019,174,349,79019,764,498,9208,896,137,170251,473,6403,508,607,550-1,804,843,000
CFO
9.36b
-68.42%
271,722,000-3,278,652,0004,742,178,0001,418,781,0007,413,981,1002,197,165,680-7,780,098,850-3,518,357,340-454,023,7003,950,368,12042,138,652,270-2,994,392,10020,490,918,610929,290,570839,871,90025,204,350,56029,642,920,0509,360,058,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hanall Biopharma Co.,Ltd, a pharmaceutical company, researches, develops, and sells pharmaceutical products in South Korea and internationally. The company offers specialty drugs and over-the-counter products for the treatment of gastric and duodenal ulcers, gastritis, cerebrovascular and peripheral blood vessel disorder, hypertension, atherosclerotic symptom, acute coronary syndrome, atherothrombosis and thromboembolism, diabetes, osteoporosis, chronic kidney failure, hypothyroidism, vitamin D-resistant rickets, osteomalacia, erectile dysfunction, prostatic hyperplasia, candidiasis, various fungal infections, prostate cancer, formal, constipation, thin stools, bloating, bowel abnormal fermentation, and hemorrhoids. The company was founded in 1973 and is based in Seoul, South Korea.
IPO date
Dec 18, 1989
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT